NCT00152581View on ClinicalTrials.gov

Analysis of the Duration of Combination Therapy That is Necessary for HCV Genotype 1 Eradication

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2002

Conditions
Chronic Hepatitis C, HCV Genotype 1
Interventions
DRUG

Pegylated interferon-alfa2a (Pegasys); ribavirin

Trial Locations (1)

WC1E 6HX

Hepatitis Clinic, University College London Hospital

All Listed Sponsors
lead

University College London Hospitals

OTHER

NCT00152581 - Analysis of the Duration of Combination Therapy That is Necessary for HCV Genotype 1 Eradication | Biotech Hunter | Biotech Hunter